Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Amphastar Pharmaceuticals (AMPH) PT Raised to $25 at Needham & Company
November 9, 2018 9:14 AM ESTNeedham & Company analyst Serge Belanger raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $25.00 (from $20.00) while maintaining a Buy rating.
Belanger commented, "AMPH delivered 3Q18 results that beat both top- and bottom-line Street consensus estimates, benefiting from a surprisising significant uptick in... More
